ERS Respiratory Channel

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

Abstract

Background: Biologic therapies have made clinical remission a viable goal in patients (pts) with severe eosinophilic asthma (SEA).

Aim: We describe clinical remission in pts with SEA, with/without prior biologic experience, over 2 years of benralizumab in the large-scale, real-world, XALOC-1 study programme.

Methods: This analysis of retrospective, multinational data assessed clinical remission rates over 2 years. Remission was defined as: exacerbation free during the entire follow-up period (48 or 96 weeks [wks]); asthma symptom control (Asthma Control Test score ?16 or 6-item Asthma Control Questionnaire score <1.5) and no maintenance oral corticosteroid use, assessed at Wk 48 or 96.

Results: Pts (n=1070) had a mean (SD) age of 55.2 (13.7) years; 58.7% were female; 61.9% were biologic-naïve and 37.8% -experienced (omalizumab 43.6%, mepolizumab, 62.6%, reslizumab, 8.2%). 45.1% of pts achieved remission by Wk 48, 37.5% by Wk 96 (Figure). Of pts who met remission criteria at Wk 96, 59.3% had sustained remission from Wk 48. Remission rates were higher in biologic-naïve vs -experienced pts, and in omalizumab- vs mepolizumab-experienced pts, at all timepoints (Figure).

Conclusion: Clinical remission is a realistic, sustainable goal up to 2 years for pts with SEA receiving benralizumab, regardless of prior biologic experience.

Funding: AstraZeneca

Abstract

#{title}